CG:603087 Gan & Lee Pharmaceuticals Co Ltd

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin and its analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; and Raplin 30, an insulin aspart 30 injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.

67.26 CNY
As of 01/17/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Medical Instruments & Supplies
Index country:  China
Country of incorporation:  China
IPO date:  06/29/2020
Stock exchange:    Shanghai Stock Exchange
Exchange country:   China
Market cap:   37,903,949,824 CNY
Current dividend yield:   0.56%
Sedol:      BMQBVG3

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy